{"id":4000,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"1993-12-06","marketCap":12354,"name":"Incyte Corp","phone":"13024986700.0","outstanding":224.09,"symbol":"INCY","website":"https://www.incyte.com/","industry":"Biotechnology"},"price":64.5275,"year":2024,"month":7,"day":18,"weekday":"Thursday","title":"Ownership Structure of Incyte Corp Stock","date":"2024-07-18","url":"/posts/2024/07/18/INCY","content":[{"section":"Institutional Investors","text":"As of the most recent filing, institutional investors hold approximately 88.36% of Incyte Corp stock. The largest institutional shareholder is The Vanguard Group, Inc., with a stake of 7.31%. BlackRock, Inc. also holds a significant position with 7.24% ownership. Other major institutional investors include State Street Corporation (4.28%) and FMR LLC (3.32%)."},{"section":"Insider Ownership","text":"Insider ownership of Incyte Corp stock is approximately 0.81%. The largest insider shareholder is Dr. Paul A. Friedman, President, and CEO of Incyte Corp, with a 0.13% stake. Other significant insider shareholders include Dr. Hervé Hoppenot, Chairman of the Board (0.11%), and Ms. Paula J. Swain, EVP \u0026 General Counsel (0.08%)."},{"section":"Major Shareholders","text":"The major shareholders of Incyte Corp stock include institutions such as The Vanguard Group, Inc. (7.31%), BlackRock, Inc. (7.24%), State Street Corporation (4.28%), and FMR LLC (3.32%). Furthermore, key insider shareholders are Dr. Paul A. Friedman (0.13%), Dr. Hervé Hoppenot (0.11%), and Ms. Paula J. Swain (0.08%)."}],"tags":["LongSignals","Long","Biotechnology"],"news":[{"category":"company","date":1721221894,"headline":"Is Incyte Corporation's (NASDAQ:INCY) Recent Stock Performance Tethered To Its Strong Fundamentals?","id":128742673,"image":"https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","symbol":"INCY","publisher":"Yahoo","summary":"Incyte's (NASDAQ:INCY) stock is up by a considerable 21% over the past three months. Given that the market rewards...","url":"https://finance.yahoo.com/news/incyte-corporations-nasdaq-incy-recent-131134015.html"},{"category":"company","date":1721206560,"headline":"Most shorted S\u0026P 500 stocks in June","id":128730896,"image":"","symbol":"INCY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3560737614"},{"category":"company","date":1721066460,"headline":"Incyte (INCY) Gains 19.6% in Three Months: Here's Why","id":128704609,"image":"https://media.zenfs.com/en/zacks.com/f91db6bb14dedc17d5edb20f29c41da3","symbol":"INCY","publisher":"Yahoo","summary":"Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.","url":"https://finance.yahoo.com/news/incyte-incy-gains-19-6-180100316.html"},{"category":"company","date":1720618140,"headline":"Company News for July 10, 2024","id":128658622,"image":"https://media.zenfs.com/en/zacks.com/8b1af3ad732e2465fff459276b3ebba8","symbol":"INCY","publisher":"Yahoo","summary":"Companies In The Article Are:INCY, LW,PATH and HELE","url":"https://finance.yahoo.com/news/company-news-july-10-2024-132900891.html"},{"category":"company","date":1720526400,"headline":"Incyte to Report Second Quarter Financial Results","id":128640526,"image":"https://media.zenfs.com/en/business-wire.com/1ca0d9227b99643f0d50b31d99a99993","symbol":"INCY","publisher":"Yahoo","summary":"WILMINGTON, Del., July 09, 2024--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 30, 2024.","url":"https://finance.yahoo.com/news/incyte-report-second-quarter-financial-120000345.html"},{"category":"company","date":1720522380,"headline":"The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024","id":128700097,"image":"https://media.zenfs.com/en/investorplace_417/906ddd37036be127bc725195cc16745a","symbol":"INCY","publisher":"Yahoo","summary":"Cathie Wood was the hottest money manager in the game in 2020. Her Ark Invest family of funds offered investors blistering returns on their money. At one point, she more than doubled their money in a year. She has run hot and cold since. Last year, she was white hot, but in 2024, the investing guru has cooled off again. All of her funds are trailing both the S\u0026P 500 and the tech-heavy Nasdaq 100 by double-digit percentages. That suggests there are many undervalued Cathie Wood stocks to choose fr","url":"https://finance.yahoo.com/news/3-most-undervalued-cathie-wood-105300450.html"},{"category":"company","date":1720519200,"headline":"7 Cheap Biotech Stocks With Major Upside Potential","id":128699047,"image":"https://media.zenfs.com/en/investorplace_417/0ebd190752b6419fc43b31a5af5f5413","symbol":"INCY","publisher":"Yahoo","summary":"Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market value of the ecosystem should be massive. Grand View Research estimates that it would be worth $3.88 trillion by 2030. Still, the opportunistic investor may want to consider cheap biotech stocks. It comes down to adding more pieces on the table. You can always elect the high-flying names that command ri","url":"https://finance.yahoo.com/news/7-cheap-biotech-stocks-major-100000301.html"},{"category":"company","date":1720518529,"headline":"Incyte Reports Inducement Grants under Nasdaq Listing Rule 5635(4)","id":128635631,"image":"","symbol":"INCY","publisher":"Finnhub","summary":"WILMINGTON - Incyte today announced that it granted restricted stock unit awards representing an aggregate of 14,577 shares of the Company's common stock and stock option awards to purchase an...","url":"https://finnhub.io/api/news?id=9097c8c53c7b13e5d91822b4bb869feebf80e380e67e488da413c0537a38f6f2"},{"category":"company","date":1720470600,"headline":"Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","id":128629827,"image":"https://media.zenfs.com/en/business-wire.com/3e2689e7c4aaff6bdc862d5f38e4cead","symbol":"INCY","publisher":"Yahoo","summary":"WILMINGTON, Del., July 08, 2024--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://finance.yahoo.com/news/incyte-reports-inducement-grants-under-203000960.html"},{"category":"company","date":1720174800,"headline":"3 Highly Rated Biotech Stocks for Your July Buy List","id":128652738,"image":"https://media.zenfs.com/en/investorplace_417/a8f240deb0f658f7577d44d429a00f38","symbol":"INCY","publisher":"Yahoo","summary":"The healthcare sector continues to be a hotbed of innovation, with biotechnology leading the charge. From groundbreaking gene therapies to next-generation cancer treatments, biotech companies are pushing the boundaries of medicine and transforming patient care. This year has already witnessed significant advancements in the biotech space. We’ve seen successful clinical trials, regulatory approvals for life-changing therapies and major acquisitions within the industry. For instance, on July 2, th","url":"https://finance.yahoo.com/news/3-highly-rated-biotech-stocks-102000888.html"}]}